The drug company said tests of its cannabis formulations and medicinal mushrooms, developed by Canadian company Aion Therapeutic, were effective in killing HER2 + breast cancer cells, the cause of about 20% of all breast cancers
According to the PLC (), a combined formulation of its medicinal cannabis treatment and the medicinal mushrooms developed by Canadian company Aion Therapeutic Inc has been effective in killing HER2 + breast cancer cells, the cause of about 20% of all breast cancers.
The pharmaceutical company said tests by the independent laboratory BIOENSIS showed that its medicinal cannabis formulations are “particularly effective” at directly killing live HER2 + cancer cells, while Aion’s medicinal mushroom formulations are most effective at stimulating T-cell production of the immune system to produce HER2 + attack and kill cancer cells.
WATCH: Dr. Barnhill of Apollon Formies, inspired by the death of his mother, to cure cancer nausea with THC-guided drugs
When the two formulations were combined, Apollon said that almost 100% of HER2 + cells were killed in 3D cell cultures.
Apollon’s cannabis formulation was developed by its subsidiary Apollon Formulies Jamaica, while the tests were conducted under a joint testing agreement between the parties under a research and development license issued by the Jamaican government’s Cannabis Licensing Authority.
“Cannabinoids have been observed to exert ‘anti-tumor’ effects in a number of ways, including killing cancer cells directly, as well as inhibiting transformed cell growth and metastasis. Apollon Jamaica uses results of its proprietary artificial intelligence-based analysis of strain genetics. Has some of its We are pleased that our formulations have been validated by independent laboratory tests to kill HER2 + breast cancer cells in 3D cell culture through direct cytotoxicity, “said Stephen, CEO of Apollon Barnhill in a Explanation.
“It is our theory that using a combination of cancer therapies, particularly those with separate treatment pathways, may have advantages over single-agent-based strategies, as they can allow for simultaneous or serial targeting of tumor growth, progression, and / or spread at different levels Levels in an effort to kill cancer cells, ”he added.